Sincalide: complete guide

Sincalide is a synthetic cholecystokinin octapeptide first approved by FDA as Kinevac in 1976. This guide covers its structure, mechanism, labeled diagnostic uses, evidence and warnings.

Complete guide5 min read

Key takeaway

FDA first approved sincalide as Kinevac on July 21, 1976. It is an octapeptide, a chain of 8 amino acids, with a molecular weight of 1,143.3 g/mol in PubChem. In a randomized trial of 243 newborns, it did not prevent a form of infant liver cholestasis, an unapproved use.

At a glance

Article typeComplete guide
Regulatory statusFDA-approved“Drugs@FDA lists the original approval of Kinevac on July 21, 1976.” (this article)
ClassGut & digestion
Body systemsGut
Studies cited2 in this article · 2 across 1 article on Sincalide
Related productsResearch peptide catalog

Sincalide is a synthetic eight-amino-acid peptide copied from the active end of cholecystokinin, a gut hormone. It makes the gallbladder contract and is used as an aid in diagnostic tests of the gallbladder, pancreas and small bowel. This guide covers its structure, mechanism, labeled uses, evidence and warnings, with sources checked on November 17, 2026.

Quick answer: Sincalide is a prescription diagnostic peptide sold as Kinevac and under its generic name. Its label covers stimulating gallbladder contraction, stimulating pancreatic secretion together with secretin, and speeding a barium meal through the small bowel. It has no boxed warning. The most common side effects are abdominal discomfort or pain and nausea.

Vitrapep does not sell sincalide; this page is a reference summary of published research and regulatory information.

What is sincalide?

The Kinevac label describes sincalide as “a synthetically-prepared C-terminal octapeptide of cholecystokinin” (Kinevac label, 2023). Cholecystokinin, or CCK, is a hormone the gut releases after a meal. The C-terminal octapeptide is the last eight amino acids of that hormone, often called CCK-8.

It counts as a peptide because it is a short chain of amino acids. ChEBI, quoted in PubChem, simply states: “Sincalide is an oligopeptide.” The label’s chemical name gives the order: aspartic acid, a sulfated tyrosine, methionine, glycine, tryptophan, methionine, aspartic acid and phenylalaninamide. PubChem lists the formula as C49H62N10O16S3 and the molecular weight as 1,143.3 g/mol (PubChem CID 9833444). Our overview of peptide hormones covers gut hormones like CCK.

Drugs@FDA lists the original approval of Kinevac on July 21, 1976. The application is NDA 017697, held by Bracco (Drugs@FDA). DailyMed also lists sincalide labels from Maia Pharmaceuticals, Fresenius Kabi and Fosun Pharma.

Table 1

Sincalide: key facts

Fact Detail
Structure type Synthetic linear octapeptide (CCK-8) with a sulfated tyrosine
Class Cholecystokinin analog; diagnostic agent
Molecular formula C49H62N10O16S3
Molecular weight 1,143.3 g/mol
First FDA approval July 21, 1976 (Kinevac, NDA 017697)
Brand names (US) Kinevac; generic sincalide from several makers

How does sincalide work?

Sincalide stands in for natural CCK. The label states that it “stimulates gallbladder contraction and reduction in size.” It adds that the resulting release of bile “is similar to that which occurs physiologically in response to endogenous cholecystokinin” (Kinevac label, 2023). Endogenous means made by the body itself.

Its effects reach beyond the gallbladder. The label says sincalide “also stimulates pancreatic secretion and intestinal motility,” causing contraction of the pylorus and slower stomach emptying. Given together with secretin, it raises the volume of pancreatic juice and its output of bicarbonate and enzymes. That combined effect lets doctors test pancreatic function by analyzing fluid from the duodenum. See our secretin guide for the partner hormone.

What is sincalide approved for?

The Kinevac label lists three uses in adults:

  • to “stimulate gallbladder contraction, as may be assessed by various methods of diagnostic imaging,” or to collect a sample of concentrated bile from the duodenum for analysis;
  • to “stimulate pancreatic secretion in combination with secretin” before collecting duodenal fluid for analysis; and
  • to “accelerate the transit of a barium meal through the small bowel.”

All three are diagnostic uses. Sincalide does not treat gallbladder or pancreatic disease; it helps doctors measure how these organs work (Kinevac label, 2023). Maia’s sincalide label, marketed under NDA 210850, lists the same three uses (Maia sincalide label, 2023).

What does the key evidence show?

Normal values for gallbladder emptying. Sincalide is used with cholescintigraphy, a nuclear medicine scan that measures gallbladder ejection fraction. That is the share of bile the gallbladder empties. A multicenter human study of 60 healthy volunteers at 4 medical centers set normal values for this test. For the method with the least variability, the lower limit of normal was 38% (Ziessman et al., 2010).

A negative prevention trial. Researchers also tested sincalide outside its label. A multicenter, double-blind, randomized, controlled trial enrolled 243 newborns at high risk of cholestasis linked to parenteral nutrition. Cholestasis means reduced bile flow. The primary outcome was conjugated bilirubin, a blood marker of cholestasis.

Sincalide “did not significantly affect” conjugated bilirubin levels, and secondary outcomes were also unaffected. The authors concluded that it “failed to reduce significantly the incidence” of this cholestasis. They advised against using it for prevention (Teitelbaum et al., 2005). The registry record is NCT00004414.

What side effects does the label list?

The Kinevac label has no boxed warning. It states: “The most frequent adverse reactions (20% or greater) are gastrointestinal: abdominal discomfort or pain, and nausea.” Less common reports include allergic reactions up to anaphylaxis, seizures, headache, fainting, vomiting, flushing, diarrhea and an urge to defecate.

The warnings section covers four topics:

  • anaphylaxis and other serious allergic reactions, partly because Kinevac contains a sulfite;
  • passage of small gallstones when the gallbladder contracts;
  • gastrointestinal reactions such as nausea; and
  • preterm labor or miscarriage, because of the drug’s effect on smooth muscle.

Contraindications are allergy to sulfites or sincalide, and intestinal obstruction (Kinevac label, 2023).

What is sincalide’s regulatory status, and how is it used in research?

Sincalide is a prescription drug in the United States. Drugs@FDA lists Kinevac’s marketing status as prescription, with Bracco as the holder. Several other companies market sincalide under the generic name.

In physiology research, CCK-8 serves as a tool to empty the gallbladder on demand. One completed study, led by Filip Krag Knop, used CCK-8 in 10 healthy people. It tested whether gallbladder emptying triggers release of GLP-1, a gut hormone that affects blood sugar (NCT01656057). That is a research use in human volunteers, not a labeled indication.

Frequently asked questions about sincalide

Is sincalide a peptide?

Yes. It is a synthetic octapeptide, the last eight amino acids of the hormone cholecystokinin.

Is sincalide the same as CCK-8?

Yes. Sincalide is the drug name for the C-terminal octapeptide of cholecystokinin, often called CCK-8.

When was sincalide approved?

Drugs@FDA lists the original approval of Kinevac on July 21, 1976.

Does sincalide treat gallbladder disease?

No. Its labeled uses are diagnostic. It makes the gallbladder contract so a test can measure how it works.

Does sincalide have a boxed warning?

No. Its warnings cover serious allergic reactions, passage of small gallstones, gastrointestinal reactions and pregnancy risks.

What to know now

  • Structure: synthetic octapeptide (CCK-8) with a sulfated tyrosine; 1,143.3 g/mol.
  • Approval: Kinevac, July 21, 1976; prescription only.
  • Mechanism: mimics cholecystokinin to contract the gallbladder and stimulate pancreatic secretion.
  • Label: three diagnostic uses involving the gallbladder, pancreas and small bowel.
  • Evidence: normal ejection fraction values from a 60-volunteer study; no benefit in a 243-infant prevention trial.
  • Safety: no boxed warning; abdominal pain and nausea most common.

What we’re watching

Further Kinevac and generic sincalide label revisions on DailyMed, last revised in October and November 2023. Related guides: secretin, glucagon and peptide hormones.

More for gut

All 11 compounds for gut

Sources: Bracco Diagnostics Inc 2023, KINEVAC (sincalide) prescribing information; U.S. Food and Drug Administration. Drugs@FDA: NDA 017697 (KINEVAC) . Retrieved November 17, Drugs@FDA: NDA 017697 (KINEVAC); National Center for Biotechnology Information 2026, PubChem compound summary for CID 9833444, sincalide; Maia Pharmaceuticals 2023, Sincalide prescribing information; Ziessman 2010, Journal of Nuclear Medicine, 51; Teitelbaum 2005, Pediatrics, 115; University of Michigan 1999; Knop 2012, The impact of gall bladder emptying and bile acids on the human GLP-1-secretion; U.S. National Library of Medicine 2026, DailyMed search results: sincalide. All 9 citations

Back to the research library

References

  1. Bracco Diagnostics Inc. (2023). KINEVAC (sincalide) prescribing information (revised 10/2023). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1408aabb-6982-48e5-ae9f-504ec43b0003
  2. U.S. Food and Drug Administration. Drugs@FDA: NDA 017697 (KINEVAC). Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017697
  3. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 9833444, sincalide. Retrieved November 17, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/9833444
  4. Maia Pharmaceuticals, Inc. (2023). Sincalide prescribing information (revised 11/2023). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4149af34-7b3d-4200-9609-ea856b1d6aab
  5. Ziessman, H. A., et al. (2010). Sincalide-stimulated cholescintigraphy: A multicenter investigation to determine optimal infusion methodology and gallbladder ejection fraction normal values. Journal of Nuclear Medicine, 51(2), 277-281. https://doi.org/10.2967/jnumed.109.069393
  6. Teitelbaum, D. H., et al. (2005). Use of cholecystokinin-octapeptide for the prevention of parenteral nutrition-associated cholestasis. Pediatrics, 115(5), 1332-1340. https://doi.org/10.1542/peds.2004-1014
  7. University of Michigan. (1999). Sincalide (cholecystokinin octapeptide) versus placebo in neonates at high risk for developing parenteral nutrition associated cholestasis (ClinicalTrials.gov ID NCT00004414). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT00004414
  8. Knop, F. K. (2012). The impact of gall bladder emptying and bile acids on the human GLP-1-secretion (ClinicalTrials.gov ID NCT01656057). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT01656057
  9. U.S. National Library of Medicine. (2026). DailyMed search results: sincalide (5 labels). Retrieved November 17, 2026, from https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=sincalide